Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas

BioTechniques

Volumn 39, Issue 5, 2005, Pages 755-761

  Kringen, Pedro ^a   Bergamaschi, Anna ^a   Due, Eldri Undlien ^a   Wang, Yun ^a   Tagliabue, Elda ^b   Nesland, Jahn M ^a   Nehman, Aune ^c   Tönisson, Neeme ^c   Børresen Dale, Anne Lise ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ARRAYS; ELECTROPHORESIS; MUTAGENESIS; NUCLEIC ACIDS; TUMORS;

ARRAYED PRIMER EXTENSION; GENOTYPING MICROARRAY; MISSENSE MUTATION; TUMOR SUPPRESSOR GENE TP53;

ONCOLOGY;

PROTEIN P53; ANTISENSE OLIGONUCLEOTIDE; DNA FRAGMENT; PRIMER DNA;

ARTICLE; BIOTECHNOLOGY; BREAST CARCINOMA; GENE DELETION; GENE INSERTION; GENOTYPE; HUMAN; MISSENSE MUTATION; NUCLEOTIDE METABOLISM; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; STAINING; ALLELE; BREAST TUMOR; CHEMISTRY; CODON; DNA MICROARRAY; DNA SEQUENCE; ELECTROPHORESIS; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MUTATION; OVARY TUMOR; POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ALLELES; BREAST NEOPLASMS; CELL LINE, TUMOR; CODON; DNA FRAGMENTATION; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; ELECTROPHORESIS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33644873230     PISSN: 07366205     EISSN: None     Source Type: Journal    
DOI: 10.2144/000112000     Document Type: Article

References (17)

1. Børresen-Dale, A.L. 2003. TP53 and breast cancer. Hum. Mutat. 21:292-300.
2. Børresen, A.L., T.I. Andersen, J.E. Eyfjord, R.S. Cornelis, S. Thorlacius, A. Borg, U. Johansson, C. Theillet, et al. 1995. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 14:71-75.
3. Sjögren, S., M. Inganas, T. Norberg, A. Lindgren, H. Nordgren, L. Holmberg, and J. Bergh. 1996. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst. 88:173-182.
4. Bull, S.B., H. Ozcelik, D. Pinnaduwage, M.E. Blackstein, D.A. Sutherland, K.I. Pritchard, A.T. Tzontcheva, S. Sidlofsky, et al. 2004. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J. Clin. Oncol. 22:86-96.
5. Aas, T., J.E. Varhaug, J. Kolnes, J.A. Soreide, and P.E. Lonning. 1994. Primary treatment of locally advanced breast cancer with neoadjuvant chemotherapy. [Article in Norwegian.] Tidsskr. Nor. Laegeforen. 114:668-670.
6. Geisler, S., P.E. Lønning, T. Aas, H. Johnsen, O. Fluge, D.E. Haugen, J.R. Lillehaug, L.A. Akslen, et al. 2001. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2505-2512.
7. Geisler, S., A.L. Børresen-Dale, H. Johnsen, T. Aas, J. Geisler, L.A. Akslen, G. Anker, and P.E. Lonning. 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin. Cancer Res. 9:5582-5588.
8. Bergh, J., T. Norberg, S. Sjögren, A. Lindgren, and L. Holmberg. 1995. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med. 1:1029-1034.
9. Berns, E.M., J.A. Foekens, R. Vossen, M.P. Look, P. Devilee, S.C. Henzen-Logmans, I.L. van Staveren, W.L. van Putten, et al. 2000. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res. 60:2155-2162.
10. Aas, T., A.L. Børresen, S. Geisler, B. Smith-Sorensen, H. Johnsen, J.E. Varhaug, L.A. Akslen, and P.E. Lonning. 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2:811-814.
11. Jiang, T., M. Minunni, and M. Mascini. 2004. Towards fast and inexpensive molecular diagnostic: the case of TP53. Clin. Chim. Acta 343:45-60.
12. Footz, T., M.J. Somerville, R. Tomaszewski, B. Elyas, and C.J. Backhouse. 2004. Integration of combined heteroduplex/restriction fragment length polymorphism analysis on an electrophoresis microchip for the detection of hereditary haemochromatosis. Analyst 129:25-31.
13. Tönisson, N., J. Zernant, A. Kurg, H. Pavel, G. Slavin, H. Roomere, A. Meiel, P. Hainaut, et al. 2002. Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene. Proc. Natl. Acad. Sci. USA 99:5503-5508.
14. Sørlie, T., H. Johnsen, P. Vu, G.E. Lind, R. Lothe, and A.L. Børresen-Dale. 2005. Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis. Methods Mol. Biol. 291:207-216.
15. Shumaker, J.M., J.J. Toilet, K.J. Filbin, M.P. Montague-Smith, and M.C. Pirrung. 2001. APEX disease gene resequencing: mutations in exon 7 of the p53 tumor suppressor gene. Bioorg. Med. Chem. 9:2269-2278.
16. Jaakson, K., J. Zernant, M. Kulm. A. Hutchinson, N. Tonisson, D. Glavac, M. Ravnik-Glavac, M. Hawlina, et al. 2003. Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum. Mutat. 22:395-403.
17. Børresen-Dale, A.L., R.A. Lothe, G.I. Meling, P. Hainaut, T.O. Rognum, and E. Skovlund. 1998. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin. Cancer Res. 4:203-210.